Taltz Citrate-Free: The same active ingredient with significantly less injection site pain vs the original formulation^1*
^*P<.0001; 3.5 vs 25.2 based on VAS 0-100

Hypothetical Patient

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Trust the Taltz long-term safety data^1-9

Five years of established safety experience with this IL-17A antagonist

Across 15 global PsO clinical trials²

6000+ PsO patients treated in adult studies³

17,000+ patient-years of exposure to Taltz³

The same active ingredient with significantly less injection site pain^1,4†

NO BOXED WARNINGS OR ROUTINE LAB MONITORING REQUIRED^4‡

Adjudicated IBD events were low and infrequent (0.5%)^6§

The Taltz label does not contain suicidal ideation and behavior as an adverse reaction or warning⁴

Rate of oral candidiasis was 2.2% and did not lead to treatment discontinuation^7,8

Patients treated with Taltz worldwide since launch now nearly at 239,000⁹

See long-term safety data

Injection site pain trial design

Please see long-term safety data and injection site pain trial design.

^†P<.0001; 3.5 vs 25.2 based on VAS 0-100
^‡During Taltz treatment, monitor patients for signs and symptoms of infection and for onset or exacerbation of inflammatory bowel disease. During and after treatment with Taltz, monitor patients for active tuberculosis (TB) infection.
^§There were 5 additional patients with adjudicated IBD that weren’t considered TEAEs. Total adjudicated IBD, n=31 patients (0.5%).⁶

Long-term safety data was evaluated using an integrated data set comprising 15 phase 1, 2, 3, and 4 studies in adult patients with moderate to severe plaque psoriasis.²

This analysis includes data from the beginning of the studies to the March 2020 cutoff for integrated safety data.^2,3

IL-17A=interleukin-17A; PsO=psoriasis; ISR=injection site reaction; IBD=inflammatory bowel disease; TEAE=treatment-emergent adverse event.

SELECT IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
Warnings and precautions include infections, pre-treatment evaluation for tuberculosis, hypersensitivity, eczematous eruptions, inflammatory bowel disease, and immunizations. The most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Adverse reactions that occurred in ≥1% of Taltz patients and more frequently than with placebo⁴

INTEGRATED SAFETY: UNCOVER registration trials

ADVERSE REACTIONS THROUGH WEEK 12

	Taltz 80 mg original formation every 2 weeks (n=1167)	Enbrel^® (etanercept)^‖ 50 mg twice weekly (n=287)	Placebo (n=791)
Injection site reactions	Taltz 80 mg original formation every 2 weeks (n=1167): 17%	Enbrel^® (etanercept)^‖ 50 mg twice weekly (n=287): 11%	Placebo (n=791): 3%
Upper respiratory tract infections^¶	Taltz 80 mg original formation every 2 weeks (n=1167): 14%	Enbrel^® (etanercept)^‖ 50 mg twice weekly (n=287): 8%	Placebo (n=791): 13%
Nausea	Taltz 80 mg original formation every 2 weeks (n=1167): 2%	Enbrel^® (etanercept)^‖ 50 mg twice weekly (n=287): <1%	Placebo (n=791): 1%
Tinea infections	Taltz 80 mg original formation every 2 weeks (n=1167): 2%	Enbrel^® (etanercept)^‖ 50 mg twice weekly (n=287): 0%	Placebo (n=791): <1%

INFECTIONS THROUGH WEEK 12

	Taltz 80 mg original formation every 2 weeks (n=1167)	Enbrel^® (etanercept)^‖ 50 mg twice weekly (n=287)	Placebo (n=791)
Infections	Taltz 80 mg original formation every 2 weeks (n=1167): 27%	Enbrel^‖ 50 mg twice weekly (n=287): 18%	Placebo (n=791): 23%
Serious infections	Taltz 80 mg original formation every 2 weeks (n=1167): 0.4%	Enbrel^‖ 50 mg twice weekly (n=287): 0.3%	Placebo (n=791): 0.4%

^‖US-approved Enbrel (etanercept).
^¶Upper respiratory tract infections include nasopharyngitis and rhinovirus infection.

The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild to moderate in severity and did not lead to discontinuation of Taltz.

ADDITIONAL ACTIVE COMPARATOR SAFETY INFORMATION FROM UNCOVER-2 AND -3
In the 2 clinical trials that included US-approved etanercept, an active comparator, the rate of serious adverse events during weeks 0 to 12 was 2% with Taltz and 0.7% with US-approved Enbrel, and the rate of discontinuation from adverse events was 2% with Taltz and 0.7% with US-approved Enbrel.

SAFETY DATA FROM SPIRIT-P1 AND -P2 TRIALS
Overall, patients with psoriatic arthritis had a safety profile consistent with that of patients with plaque psoriasis in UNCOVER-1, -2, and -3 trials, except for frequency of influenza (Taltz 1.3%, placebo 0.4%) and conjunctivitis (Taltz 1.3%, placebo 0%).

TALTZ PSORIASIS CLINICAL TRIALS

Demonstrated long-term safety data for half a decade and counting^2,3

Over 6000 patients across 15 clinical trials

ADVERSE EVENTS OF SPECIAL INTEREST: INCIDENCE RATES PER 100 PYS

	Total PY=17,599	Year 1 PY=5688	Year 2 PY=3390	Year 3 PY=3108 (n)	Year 4 PY=2882 (n)	Year 5 PY=2375 (n)
Serious infections	Total PY=17,599: 1.3	Year 1 PY=5688: 1.3	Year 2 PY=3390: 1.4	Year 3 PY=3108 (n): 1.7	Year 4 PY=2882 (n): 1.4	Year 5 PY=2375 (n): 1.3
Candida infections	Total PY=17,599: 1.9	Year 1 PY=5688: 3.2	Year 2 PY=3390: 2.2	Year 3 PY=3108 (n): 2.1	Year 4 PY=2882 (n): 2.3	Year 5 PY=2375 (n): 2.0
Hypersensitivity (non-anaphylaxis)	Total PY=17,599: 5.1	Year 1 PY=5688: 9.8	Year 2 PY=3390: 5.0	Year 3 PY=3108 (n): 4.4	Year 4 PY=2882 (n): 4.2	Year 5 PY=2375 (n): 3.5
Hypersensitivity (potential anaphylaxis^**)	Total PY=17,599: 0.1	Year 1 PY=5688: 0.2	Year 2 PY=3390: 0.1	Year 3 PY=3108 (n): 0.0 (0)	Year 4 PY=2882 (n): 0.0 (0)	Year 5 PY=2375 (n): 0.0 (0)
Crohn's disease^††	Total PY=17,599: 0.1	Year 1 PY=5688: 0.1	Year 2 PY=3390: 0.1	Year 3 PY=3108 (n): 0.0 (1)	Year 4 PY=2882 (n): 0.0 (1)	Year 5 PY=2375 (n): 0.1
Ulcerative colitis^††	Total PY=17,599: 0.1	Year 1 PY=5688: 0.2	Year 2 PY=3390: 0.1	Year 3 PY=3108 (n): 0.0 (1)	Year 4 PY=2882 (n): 0.0 (0)	Year 5 PY=2375 (n): 0.1
Malignancy-related (Nonmelanoma skin cancer)	Total PY=17,599: 0.3	Year 1 PY=5688: 0.5	Year 2 PY=3390: 0.2	Year 3 PY=3108 (n): 0.4	Year 4 PY=2882 (n): 0.2	Year 5 PY=2375 (n): 0.2
Malignancy-related (Malignancies excluding NMSCs)	Total PY=17,599: 0.5	Year 1 PY=5688: 0.5	Year 2 PY=3390: 0.6	Year 3 PY=3108 (n): 0.5	Year 4 PY=2882 (n): 0.6	Year 5 PY=2375 (n): 0.6
Injection site reactions	Total PY=17,599: 5.5	Year 1 PY=5688: 16.1	Year 2 PY=3390: 4.2	Year 3 PY=3108 (n): 2.2	Year 4 PY=2882 (n): 2.3	Year 5 PY=2375 (n): 1.7

^**After review of potential cases, no confirmed cases of anaphylaxis in clinical trials.¹⁰
^††Data on all suspected IBD, as identified by events potentially indicative of ulcerative colitis or Crohn’s disease, were adjudicated according to EPIMAD criteria by an external clinical review committee of gastroenterologists with IBD expertise.

When incidence rates equal 0.0, the n value is added; n=number of events.

The average and median Taltz exposure durations were 996.7 days and 718 days, respectively.¹¹

Certain adverse events, such as malignancy, require longer observation periods and larger patient exposure to ascertain risk. In the reported safety population of the psoriasis clinical trials, not all patients received the recommended dosing regimen consistent with the FDA-approved label.

PY=patient-year; NMSC=nonmelanoma skin cancer; IBD=inflammatory bowel disease; EPIMAD=Registre Epidemiologique des Maladies de l’Appareil Digestif.

Identifying Patients with Symptoms of Inflammatory Bowel Disease (IBD)

00:00-00:18
[First section of caption fades away and is replaced by second section of caption.]

Caption:
How to identify patients with symptoms of inflammatory bowel disease (IBD) and when to make a referral—Insights from a dermatologist, rheumatologist, and gastroenterologist.
PP-LI-US-0795 01/2024 © Lilly USA, LLC 2024. All rights reserved.

Lilly invited speakers to discuss a specific topic based on a series of questions and assisted in developing a script for discussion. Speakers were encouraged to include their own experience where appropriate. Some of the content in this video may therefore reflect the speakers’ personal opinions and may be specific to their own practice. Particular recommendations are those of the individual physicians and not those of Eli Lilly and Company.

00:19-00:32
[The pictures, names, and captions of the three doctors appear on screen.]

Caption:
Prof. Alexander Moschen, Gastroenterologist, Assistant Professor of Internal Medicine, Consultant Gastroenterologist, Medical University Innsbruck, Austria.
Prof. Dennis McGonagle, Rheumatologist, Professor of Investigative Rheumatology, Consultant Rheumatologist, Leeds Teaching Hospitals NHS Trust, UK.
Dr Joseph Merola, Dermatologist, Associate Physician, Brigham and Women’s Hospital, Associate Professor of Dermatology, Harvard Medical School, Boston, MA, USA.

Dr. Moschen: Hi, my name is Dr. Moschen. I'm joined by Professor McGonagle and Dr. Merola to discuss inflammatory bowel disease from our three different perspectives: gastroenterology, rheumatology, and dermatology.

00:33-00:55
[The caption is replaced by Dr. Moschen’s photograph. A diagram of the intestines with the colon highlighted with the label Ulcerative colitis appears. Then a diagram of the whole intestinal tract appears with the large intestines and then the ileum being highlighted with the label Crohn’s disease.]

Caption:
What is IBD?
Prof. Alexander Moschen, Gastroenterologist
IBD – Ulcerative colitis, Crohn’s disease

Dr. Moschen: IBD is a chronic relapsing-remitting, immune-mediated disorder characterized by inflammation in the gastrointestinal tract. Two major forms of IBD include ulcerative colitis, affecting only the colon, and Crohn's disease, which may affect the whole of the intestinal tract, but typically in a discontinuous region.

00:56-01:15
[A DNA icon within a circle appears, joined by circles representing ulcerative colitis and Crohn’s disease. Then a circle with the words immune-mediated diseases e.g. PsO, axSpA, and PsA appears. come onto the screen as he begins talking.]

Caption:
Ulcerative colitis, Crohn’s disease, immune-mediated disease e.g. PsO, axSpA, PsA

Dr. Moschen: Research shows that there is a lot of overlap in terms of genetic susceptibility between Crohn's disease, ulcerative colitis, and other immune-mediated diseases. We need to keep this relationship in mind and ask our patients with immune-mediated diseases about IBD and vice versa.

01:16-01:35
[A series of people icons appears labeled with the captions, joined by a world map with the United States, Canada, and Europe highlighted.]

Caption:
300 in 100,000; 500 in 100,000, Immune-mediated disorders

Dr. Moschen: If we look at the epidemiology of IBD, a comparable prevalence rate is observed in North America and Europe with approximately 300 to 500 cases per 100,000 inhabitants. By comparison, the incidence rate in patients with immune-mediated disorders is marginally higher.

01:36-02:11
[The caption is replaced by Prof. McGonagle’s photograph. Representative icons labeled with the captions appear and slide off screen to the left.]

Caption:
What clinical symptoms do you look for in patients who may be at higher risk of IBD?
Prof. Dennis McGonagle, Rheumatologist
Abdominal symptoms, Family history, Inflammatory markers, Anemia, Fecal calprotectin

Prof. McGonagle: In rheumatology, we will ask the patients who we suspect might have spondyloarthritis about abdominal symptoms and ask about a family history of IBD. Beyond that, we run routine blood investigations, including inflammatory markers, looking for evidence of anemia, and we may also check fecal calprotectin. And based on these findings, we may then refer the patient to our gastroenterologist to further evaluate for IBD.

02:12-02:44
[A photograph of Dr. Merola appears. Representative icons labeled with the captions appear and slide off screen to the left.]

Caption:
Dr Joseph Merola, Dermatologist
Abdominal symptoms, Family history, Blood, Mucus, Fever, Fatigue, >6-10 bowel movements, hypoalbuminemia, anemia, increased WBC, Fecal calprotectin

Dr. Merola: From a dermatologist perspective, I certainly consider it crucial to obtain the patient’s personal history, in terms of symptoms that might be relevant to IBD as well as family history. I look for red flags such as bleeding, mucus in the stool, fever, and I typically will ask about fatigue, maybe number of bowel movements throughout the day. I would also look for signs in their blood work, such as hypoalbuminemia, anemia, elevated white blood count, as well as considering a fecal calprotectin.

02:45-03:05
[The caption is replaced by Dr. Moschen’s photograph. Then later captions and representative icons animate and slide to the left.]

Caption:
What would be the main questions to ask your patient?
Prof. Alexander Moschen, Gastroenterologist
Have you experienced gastrointestinal symptoms?
Diarrhea, Blood, Mucus, Abdominal pain, >4 weeks

Dr. Moschen: I would recommend asking two simple questions. The first one is, “Have you ever experienced any gastrointestinal symptoms, namely diarrhea, blood in stool, mucus, abdominal pain that have lasted longer than four weeks?”

03:06-03:41
[Captions and representative icons animate and slide to the left.]

Caption:
Does anyone in the family suffer from IBD?
Family history, Abdominal symptoms, Fecal calprotectin
-No further testing (likely IBS)
+Further investigation required (refer to a gastroenterologist)

Dr. Moschen: And secondly, does anyone in the family suffer from IBD? If the patient has a positive family history or is reporting persistent GI symptoms, my recommendation would be to run a test for fecal calprotectin. Fecal calprotectin is the most important parameter to distinguish between inflammatory and functional gastrointestinal diseases and the results are similar to a traffic light system. If the test is negative, it might not really be necessary to do any further testing. Then it's likely IBS.

03:42-04:24
[The caption is replaced by Dr. Moschen’s photograph. Captions and representative icons animate and slide to the left.]

Caption:
How do you differentiate idiopathic gastrointestinal symptoms from real IBD?
Prof. Alexander Moschen, Gastroenterologist
How long have you had these symptoms?
Chronic diarrhea is defined as having symptoms for more than 4 weeks
In patients with immune-mediated disease, refer to a gastroenterologist if GI symptoms persist longer than 2 weeks
How rapid was the onset of symptoms?

Dr. Moschen: The first question to ask is how long have you had these symptoms? The duration of symptoms is very important. IBD is a form of chronic diarrhea and is defined as having symptoms for more than four weeks. In a patient with an immune-mediated disease, I would recommend referring to a gastroenterologist if the patient has GI symptoms for longer than two weeks. Secondly, the onset of symptoms occur very rapidly. It's likely that the problem is not IBD, then it's more likely an acute gastroenteritis caused by virus or bacteria or by food poisoning.

04:25-04:55
[A photograph of Prof. McGonagle appears. Representative icons and captions animate and slide to the left.]

Caption:
Prof. Dennis McGonagle
Rheumatologist
Abdominal symptoms
Bloody diarrhea, Mucus, Weight loss, Colitis, IBS

Prof. McGonagle: From a rheumatology perspective, if a patient’s been on an IL-17 inhibitor for psoriatic arthritis or ankylosing spondylitis for several months and they develop abdominal symptoms, but the absence of bloody diarrhea, mucus, and weight loss and clearly overt colitis and they simply have pains, which may be linked to irritable bowel, we wouldn't jump in and stop treatment.

04:56-05:06
[A photograph of Dr. Merola appears. Representative icons and captions animate and slide to the left.]

Caption:
Dr Joseph Merola
Dermatologist
Abdominal symptoms

Dr. Merola: And I agree, I'd say from the dermatology perspective, abdominal complaints, diarrhea, and GI symptoms are pretty common. So, I wouldn't be in a rush to switch treatment, particularly effective treatment, unless I really saw those true red flags.

05:07-05:27
[A photograph of Dr. Moschen appears. Captions and representative icons animate and slide to the left.]

Caption:
Prof. Alexander Moschen
Gastroenterologist
Idiopathic GI symptoms
IBD
Thank you

Dr. Moschen: So, I fully agree. So, simple questions are really useful tools to begin differentiating idiopathic gastrointestinal symptoms from real IBD. I think it's important to understand the signs and symptoms and how to manage your patients and when to refer to a gastroenterologist. Thank you very much.

05:28-05:35
Caption:
Taltz Label Language
Inflammatory Bowel Disease
Patients treated with TALTZ may be at increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ group than the placebo control group. During TALTZ treatment, monitor for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue TALTZ and initiate appropriate medical management.

05:36-05:40
Caption:
References:

David T, Ling SF, Barton A. Clin Exp Immunol. 2018;193(1):3-12.
Egeberg A, Mallbris L, Warren RB, et al. Br J Dermatol. 2016;175(3):487-492.
Graves NS. Prim Care. 2013;40(3):727-741.
Juckett G, Trivedi R. Am Fam Physician. 2011;84(10):1119-1126.
Li WQ, Han JL, Chan AT, Qureshi AA. Ann Rheum Dis. 2013;72(7):1200-1205.
Ng SC, Shi HY, Hamidi N, Underwood FE, et al. Lancet. 2018;390(10114):2769-2778.
Silverberg MS, Satsangi J, Ahmad T, et al. Can J Gastroenterol. 2005;19(Suppl A):5A-36A.

Taltz [US PI]. Indianapolis, IN, USA: Eli Lilly USA LLC, 2020.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf Accessed October 14, 2020).

05:41-05:45
Caption: Abbreviations:
axSpA=Axial Spondyloarthritis
GI=Gastrointestinal
IBD=Inflammatory Bowel Disease
IBS=Irritable Bowel Syndrome
IL-17=Interleukin-17
PsA=Psoriatic Arthritis
PsO=Psoriasis
WBC=White Blood Count

05:46-05:51
Caption:
Eli Lilly and Company would like to thank Prof McGonagle, Dr Merola and Dr Moschen for kindly providing their time and expertise for this video project. Speakers were encouraged to include their own experience where appropriate. Some of the content in this video may reflect the speakers’ personal opinions and may be specific to their own practice.

References: 1. Chabra S, Gill BJ, Gallo G, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther. 2022;Epub (Incl Suppl Inf):1-11, 1-4. https://doi.org/10.1007/s12325-022-02126-0. 2. Data on file. Lilly USA, LLC. DOF-IX-US-0251. 3. Data on file. Lilly USA, LLC. DOF-IX-US-0256. 4. Taltz. Prescribing Information. Lilly USA, LLC. 5. Data on file. Lilly USA, LLC. DOF-IX-US-0292. 6. Data on file. Lilly USA, LLC. DOF-IX-US-0265. 7. Data on file. Lilly USA, LLC. DOF-IX-US-0288. 8. Data on file. Lilly USA, LLC. DOF-IX-US-0289. 9. Data on file. Lilly USA, LLC. DOF-IX-US-0311. 10. Data on file. Lilly USA, LLC. DOF-IX-US-0255. 11. Data on file. Lilly USA, LLC. DOF-IX-US-0267.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections
Taltz may increase the risk of infection. Serious infections have occurred. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebocontrolled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. In the post-marketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors, including Taltz. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Consider anti-TB therapy prior to initiating Taltz in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Eczematous Eruptions
In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma were reported in patients receiving Taltz; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of Taltz. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing Taltz.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please see Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

Taltz is available as an 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection.

IX HCP ISI 20AUG2024

INDICATIONS

Taltz is indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Taltz is also indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Trust the Taltz long-term safety data1-9